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Background: A successful therapeutic strategy, specifically tailored to the molecular constitution of an individual
and their disease, is an ambitious objective of modern medicine. In this report, we highlight a feasibility study in
canine osteosarcoma focused on refining the infrastructure and processes required for prospective clinical trials
using a series of gene expression-based Personalized Medicine (PMed) algorithms to predict suitable therapies
within 5 days of sample receipt.
Methods: Tumor tissue samples were collected immediately following limb amputation and shipped overnight
from veterinary practices. Upon receipt (day 1), RNA was extracted from snap-frozen tissue, with an adjacent H&E
section for pathological diagnosis. Samples passing RNA and pathology QC were shipped to a CLIA-certified
laboratory for genomic profiling. After mapping of canine probe sets to human genes and normalization against a
(normal) reference set, gene level Z-scores were submitted to the PMed algorithms. The resulting PMed report was
immediately forwarded to the veterinarians. Upon receipt and review of the PMed report, feedback from the
practicing veterinarians was captured.
Results: 20 subjects were enrolled over a 5 month period. Tissue from 13 subjects passed both histological and
RNA QC and were submitted for genomic analysis and subsequent PMed analysis and report generation. 11 of the
13 samples for which PMed reports were produced were communicated to the veterinarian within the target 5
business days. Of the 7 samples that failed QC, 4 were due to poor RNA quality, whereas 2 were failed following
pathological review. Comments from the practicing veterinarians were generally positive and constructive,
highlighting a number of areas for improvement, including enhanced education regarding PMed report
interpretation, drug availability, affordable pricing and suitable canine dosing.
Conclusions: This feasibility trial demonstrated that with the appropriate infrastructure and processes it is possible
to perform an in-depth molecular analysis of a patient’s tumor in support of real time therapeutic decision making
within 5 days of sample receipt. A number of areas for improvement have been identified that should reduce the
level of sample attrition and support clinical decision making.
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The treatment of cancer is constantly evolving towards
the integration of ever advancing knowledge of disease
processes and improvements in molecular and computa-
tional technologies. Until recently, approaches towards
the treatment of cancer have been disease centric and pre-
dominantly determined on the basis of histological classi-
fication [1-3]. However, the disparate responses of patients
to a given agent with “the same” disease defined through
this method of nosology has been attributed to significant
molecular heterogeneity within phenotypically defined tu-
mors, and demands the inclusion of molecular biomarkers
towards the improved classification of cancers [4,5].
The last 20 years has seen an explosion in both genomic
and proteomic technologies, that have assisted in increas-
ing our understanding of disease heterogeneity and have
aggressively driven the focus of both drug discovery and
development towards the fundamental molecular drivers
of disease. Advances in molecular and computational
technologies now permit the global analysis of the gen-
ome, epigenome, proteome and metabolome at unprece-
dented granularity, and provide opportunities to study
disease heterogeneity within an individual and across pop-
ulations. This revolution in technologies has made the
promise of personalized medicine a reality, through which
health care can be customized/tailored for an individual
based on information derived from the patient and/or
their disease [6]. In the sub-branch of personalized medi-
cine often referred to as pharmacogenomics or precision
therapeutics, molecular biomarkers are being used with
increased frequency to identify agents with predicted
efficacy (and/or reduced toxicity). Oncology is driving
the adoption of PMed, where examples include the
recommended administration of trastuzumab for tumors
exhibiting HER-2 receptor gene amplification or protein
over-expression, tamoxifen in breast cancers overexpressing
the estrogen receptor, imatinib in the treatment of AML
harboring the BCR-ABL translocation [7], and Vemurafinib
in the treatment of melanomas carrying the BRAF
V600E/K mutation [8]. In addition to these relatively
simple drug-single biomarker rules, gene/protein panels
are increasingly being use in the diagnostic/prognostic
setting to identify patients that would best benefit from
neoadjuvant or adjuvant therapy [9-12]. Germline determi-
nants of drug response in key drug metabolism enzymes
such as CYP450 have also been identified and are being
assessed for their ability to optimize the therapeutic index
of agents in the clinic [13]. Such examples are a clear indi-
cation that the field of oncology is moving towards rational
selection of appropriate therapies for individual patients.
However, these tests are limited in that they do not pro-
vide global coverage of the genome, and are restricted to a
handful of select agents and cancer types. It is clear that a
more comprehensive and systematic approach is requiredto maximize the utility of new genomic and computa-
tional technologies and expand drug coverage, and thereby
more rapidly and broadly advance the implementation of
precision therapy in oncology.
Optimization of PMed through human clinical trials is
challenging as refinement of these methods is frequently
muddied against a background of standard of care therapy
and therapeutic refractoriness. Preclinical mouse models,
although offering the advantages of low cost, accelerated
endpoints, and ease of genetic manipulation are far from
adequate [14]. Human cancers arise spontaneously and
are polygenic involving coordinate networks of genes that
evolve over time, whilst transgenic mouse models primar-
ily involving the modulation of one or two genes to drive
rapid onset malignancies. The classical human cell line-
xenograft mouse model used predominantly in drug de-
velopment typically requires an immune compromised
background, thus eliminating the influence of a syngeneic
environment in the development of the disease. The emer-
gence of tumorgraft (patient-derived tumor xenografts)
models has advanced the field of in vivo cancer models
due to reduced genetic drift, persistence of human tumor
heterogeneity, and maintenance of the tumor micro-
environment [15,16]. However, these models also typically
require immune compromised mice and are sub-optimal
when compared to spontaneously arising cancers in non-
laboratory subjects.
To address the void between preclinical models and
clinical medicine, many researchers have increasingly turned
to comparative oncology as an alternative clinical model
of human disease. Comparative oncology describes the
study of spontaneous cancers in non-human species, most
frequently referring to those animals that are considered
pets/companions [17,18]. Canines, in particular, have rap-
idly risen to become a favored model for the study of hu-
man disease with around 400 inherited diseases that have
cognate human conditions [19]. Studies have shown that
canines are far superior models of human cancers than
rodents, being more similar histologically and molecularly
at the levels of both DNA and protein sequence [20]. Stark
similarities in the molecular drivers of disease, including
oncogenes, tumor suppressors and mutations have all
been shown to contribute to the development of cancer
in both dogs and humans [21]. Additional factors in favor
of the selection of canines as a translational model include
a shared environment, the contribution of etiological fac-
tors including nutrition, age and sex, and analogous diag-
nostic and interventional procedures used in veterinary
and human healthcare (reviewed in [17,18,22]). Genetic-
ally, canines are ideal candidates to study the fundamen-
tal genetic drivers of human disease, owing to the breed
specific proclivity of particular cancer types. This phenom-
enon has arisen following approximately 200 years of
inbreeding, restricting the genetic flow between breeds,
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associated with breed specific traits and disease [21,23].
Canines age 5-8-times more rapidly than humans, which
provides an opportunity to study diseases that are age
related [18]. Similarly, and in part due to less aggressive
disease management, cancer progression is quicker in dogs,
with the average disease-free interval being 18 months
compared to 7 years in humans [17]. This has significant
benefits as it enables shorter clinical trials, which, along-
side similar response to conventional (human) therapeutic
regimes, support the use of canine subjects in early clinical
trials. The lack of established standard of care treatments
for canines also provides an opportunity to evaluate novel
therapies and protocols in subjects with less advanced,
non-refractory (even naïve) disease, prospects that are
difficult to impossible in human patients [17].
Osteosarcoma (OSA) is an ideal disease candidate for
inter-species investigation of personalized medicine ap-
proaches. It has been shown that canine and human OSA
are analogous at a number of levels, histologically, behav-
iorally, genetically and with regards to response to therapy
(reviewed by [18,22,24]). The incidence of OSA in dogs is
20-fold greater than in humans [25], with around 10,000
canines diagnosed per year compared to approximately
2,650 primary bone tumors in humans (a statistic which
includes OSA, chondrosarcoma, Ewings sarcoma and ma-
lignant fibrous histiocytoma) [18], therefore increasing the
number of subjects that are available for recruitment into
clinical trials. OSA occurs primarily at around 7–9 years
of age [26], with large and giant breeds (e.g. Saint Bernards
Greyhounds, Great Danes, German Shepherds, Golden
Retrievers) having a 60-fold greater risk of developing
OSA [27,28]. Following amputation alone, >90% of dogs
die within a year, with cause of death being related to
the development of metastasis, typically to the lung [26].
Adjuvant chemotherapy can further improve survival from
103–175 days following surgery alone, to 262–450 days
(review – [24]). Even considering these dramatic changes
in survival time, the long-term prognosis for OSA is
morose and 2 year survival has been measured at between
10-26% [24]. It is the poor long term survival of canines
with OSA, along with the translational value for the corre-
sponding human disease, which makes this tumor an ideal
candidate for the identification of novel therapeutic agents
using PMed approaches.
In this report we outline the results of a 20 subject
feasibility study in canine osteosarcoma, with the key
goal of establishing the infrastructure and logistics for a
subsequent prospective large scale PMed trial. The
design of this study was not intended to validate the
clinical utility of a PMed report in dogs with cancer.
We describe the utility of global gene expression profiling
of osteosarcomas from canine patients, which in parallel
with advances in laboratory procedures, bioinformaticstools and a physician reporting interface permits the
application of real-time genomic medicine in the con-
text of veterinary medicine. Gene expression profiling
is a tool that has been used by other groups to examine
canine osteosarcoma to identify differentially expressed
genes that can stratify patients as short or long-term
survival [29] and identify biomarkers and pathways as-
sociated with patient prognosis [30].
The PMed system utilized here is an assembly of 5
predictive methodologies that rank the overall drugs pre-
dictions weighted by the number of methods which predict
the drug, frequency of inclusion (multiple targets for a
drug) and strength of prediction (high differential expres-
sion above the normal reference). The PMed system is
drug centric and focused around 183 FDA approved
medications (see Additional file 1: Table S1). Drug target
expression [31] and drug sensitive/resistant Biomarker
rules [32] are both linked directly to the expression levels
of individual genes. Two of the methods namely Drug
sensitivity signatures – PGSEA [33] and Drug Response
Signatures-CMAP [34], use global gene expression pat-
terns which have been associated with drug effectiveness.
The fifth method uses a global gene-gene interaction data-
base, to identify putative drug targets based on topological
analysis of differentially expressed genes that are up or
downstream of transcriptional events (Network Target
activity [35]). Global gene expression analysis (microarray)
has been used in both a clinical trial where it was shown
to benefit progression free survival [32] and in vitro to bet-
ter predict pharmacological response [36].
Within this investigational trial, we established a num-
ber of objectives including, a) to establish a timely process
for the collection, shipping, processing and diagnosis of
tumor samples from canine osteosarcoma patients, and b)
to determine the feasibility of generating a PMed report
from predictive modeling of canine tumor-derived gene
expression data within 5 business days of sample receipt.
Although this study was not designed to include a treat-
ment arm, we collected the opinions of the practicing
veterinarians regarding the potential clinical utility of the
PMed report. We identified that, while the presentation of
the PMed report to the veterinarian in a timely fashion is
critical to support the clinical management of the disease,
the interpretation and implementation of the report by
the clinician is essential for the success of PMed Trials
and clinical adoption in the future.
Methods
Study overview
The study design and overall processes are summarized
in Figure 1. In brief, the study involved the identification
and recruitment of 20 mixed breed or purebred dogs
with suspected appendicular OSA. The MiniMax approach
was used to identify 20 patients as a suitable sample size
Figure 1 Process diagram defining the steps and timing of the osteosarcoma PMed feasibility study. The figure highlights the numerous
steps, which are grouped by day (color), that were followed in order to produce a PMed report in 5 business days from the receipt of the sample.
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rate due to sample quality and diagnosis was conserva-
tively estimated at 25% (5 patients). In this regard an
initial patient population of 20 patients provided suffi-
cient power for statistical significance if 70% of the sam-
ples (11 of 15) were completed in the 5-day targeted
time limit. The presumptive diagnosis of OSA was based
on review of limb radiographs or from histology performed
pre-study. Study dogs were screened and samples collected
at Animal Clinical Investigation (ACI) network clinics. Eth-
ical approval for this study was granted by the respective
Institutional Animal Care and Use Committees (IACUC)
at the Van Andel Research Institute (VARI), Zoetis and
Animal Clinical Investigations (ACI). All procedures and
veterinary care provided to each patient was performed by
trained veterinary specialists who followed standard clin-
ical or protocol driven procedures as documented in the
study documentation training files. For those patients
that met the inclusion criteria, the amputation surgerywas scheduled at which time the tumor collection was
performed. The appropriate samples were sent to VARI,
processed and submitted to Clinical Reference Labora-
tory (CRL) for genomic profiling. Following receipt of
the Affymetrix gene expression data from CRL, it was
imported into VARI’s database and input into the PMed
analysis/reporting system. The PMed report was then
distributed to ACI, who further distributed to the col-
lection sites and obtained responses to a questionnaire
regarding the clinical utility of the provided PMed report.
Study eligibility
Once written owner consent had been obtained by the
clinical site, inclusion/exclusion criteria, patient demog-
raphy and physical exam data were evaluated by the in-
vestigator. If not previously performed, diseased limb
radiographs and interpretation (required) and abdominal/
thoracic radiographs (if determined necessary by the
Investigator) were performed, evaluated and results recorded.
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enrolled in the study and amputation scheduled.
Site training
Prior to the start of the study, training was provided to
each of the participating veterinary practices with
regards to the sampling of the tumor from the ampu-
tated limbs. Specific instructions were provided as to
where best to harvest tumor tissue to minimize normal
tissue contamination and bone involvement which could
complicate downstream procedures, e.g. cryo-sectioning
of snap frozen tissue for RNA extraction and H&E sec-
tioning. The primary site of harvest was designated as
grossly viable, unmixed tissue present at the advancing
front of the tumor. This site was commonly identified
outside of the marrow space, and was evident in the ma-
jority of cases. The medullary cavity was identified as the
secondary site of harvest.
Normal tissue reference
The purpose of the reference set is to facilitate compara-
tive analysis of the fundamental differences of the tumor
versus a biologically appropriate denominator, i.e. normal
tissue capturing the cell(s) of origin of the tumor. Due to
the practical challenges in obtaining breed, age and sex
matched disease-free normal bone in a study that was
open to all breeds, combined with the need to have the
reference set available prior to the start of enrollment,
five total bone samples (cortical bone and marrow) were
collected from 5 disease free Beagles. These five normal
samples were processed identically to the tumor samples
in order to provide a tissue specific reference for the
tumor samples. Standard statistics consisting of mean
and standard deviation were compiled for each probeTable 1 Study inclusion and exclusion criteria
Inclusion criteria Ex
Client-owned pet dogs ≥ 1 year of age, any gender and weight. A
Informed owner consent prior to enrollment screening. Pr
Suspected diagnosis of primary appendicular OSA (+/− metastasis) via
radiographs and physical exam or confirmed diagnosis based cytology




Any disease stage. Pr










Qset across the reference samples. The tumor sample probe
sets intensities were transformed to Z-Score by utilizing
the reference sample probe set mean and standard devi-
ation. This score was subsequently utilized by the PMed
methods to suggest possible therapies.
Tumor harvest
Following determination of eligibility and obtaining owner
informed consent, amputation surgery was scheduled.
Radiographs of the diseased limb were collected prior to
amputation to guide the best site for tumor harvest. At
the time of the surgery, immediately post amputation of
the limb, up to 5 tumor specimens (measuring approxi-
mately 4 mm3 each) were obtained per patient. Sample
requirements and prioritizations are described in Table 2.
Samples numbered 1–3 were mandatory collections,
whereas samples numbered 4–5 were optional and only
collected if excess representative tumor tissue was avail-
able. Sample 1 (formalin fixed) was sent to the collection
sites’ pathologist as per normal practice for diagnostic
evaluation. Samples 2–5 were shipped immediately to
VARI using priority overnight delivery; snap frozen sam-
ples were shipped on dry ice, whereas the formalin fixed
tissue was shipped on −20°C ice packs.
Tissue processing
Upon receipt at VARI, the samples were logged and
processed immediately. For the purpose of this study, Day
1 was considered to be the time at which tissue processing
(RNA isolation and pathology) commenced. In the case
where samples were received on a Friday (or on the week-
end), day 1 automatically defaulted to the next business
day. When sample processing was delayed, formalin fixed
samples were transferred to 70% ethanol (to avoid overclusion criteria
nticipated poor owner compliance.
egnant or likely to become pregnant.
ceiving/have received treatment for cancer including chemotherapy,
sphosphonate therapy, prednisone therapy, radiation therapy or
munotherapy, other than Non-steroidal Anti-inflammatory Drugs (NSAIDS).
eviously amputated limb as a result of OSA.
oncurrent malignancy that is non-appendicular OSA.
imary cancer originated at an anatomical sites other than appendicular
SA.
ther serious systemic disorder incompatible with this study.
cupuncture treatment less than 2 weeks prior to sample collection day
ogs that have commenced acupuncture > 2 weeks prior to Day 0 can be
cluded but they must stay on their acupuncture treatment during the
udy period).
ogs that are participating in another clinical trial, (subjects are allowed to
roll on a trial after the samples have been collected).
uality Control (QC) failure (histopathological or genomic).
Table 2 Sample prioritization and procurement
Sample # Preparation Purpose Required Destination and shipping conditions
1 Formalin Confirmatory histological diagnosis Yes Site selected diagnostic pathology
2 Snap Frozen Genomic profiling (PMed) and Histological diagnosis1 Yes VARI (dry ice)
3 Formalin Histological diagnosis2 Yes VARI (wet ice)
4 Snap Frozen Back up/tissue banking If tissue is available VARI (dry ice)
5 Formalin Backup/tissue banking If tissue is available VARI (wet ice)
1 Assessment of tumor content (% tumor by nuclei, % normal tissue by nuclei, % necrosis).
2 Back-up source for assessment of tumor content if no sections available from Snap frozen tissue.
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frozen samples were stored at −80°C.
Snap frozen
The snap frozen tissue was maintained on dry ice and
immediately embedded in Optimal Cutting Temperature
(Tissue-Tek® O.C.T.) media, which was used to hold the
tissue in position during cryosectioning. When possible,
two 5 μM sections above and below preparative RNA
cuts were taken (mounted together on a single slide) and
stained with hematoxylin and eosin (H&E). The H&E slides
were scanned using an Aperio ScanScope XT (Aperio,
Vista, CA.), and uploaded to a centralized location for
evaluation by an off-site veterinary pathologist. In between
the H&E sections, 8-10x 50 μM slices were collected for
RNA extraction.
Formalin fixed
Due to the production of mineralized osteoid by osteo-
sacrcomas which can hinder the sectioning of the tissue,
the formalin fixed sample was decalcified for 3 hours in
Formic-Decal solution (Rowley Biochemical, MA), followed
by a 1 hr. wash in running tap water. The tissue was
subsequently processed overnight into paraffin, embed-
ded, sectioned and stained with H&E. These slides were
also scanned using the Aperio ScanScope XT and the
image uploaded to a centralized location for review by
the veterinary pathologist.
RNA extraction
Total RNA was isolated directly from the OCT sections
using Trizol, with an initial homogenization for 2 minutes
at 40 oscillations/second using the TissueLyser LT (Qiagen),
followed by a DNase digestion and RNA clean-up using
Qiagen RNeasy Mini Kit. Following elution in H2O, the
RNA was analyzed spectrophotometrically (Nanodrop) to
determine RNA yield and purity (A260/280). RNA integ-
rity was subsequently determined using the Agilent RNA
6000 Nano Kit on the Agilent Bioanalyzer 2100 (Agilent
Technologies, Inc. CA.). In order for samples to proceed
to Affymetrix GeneChip profiling, three RNA QC parame-
ters had to be met; RNA yield >20 ng, A260/280 ≥1.8, and
an RNA Integrity Number (RIN) ≥ 6.0. The RNA integritynumber is generated by an algorithm which uses the en-
tire electrophoretic trace of the RNA sample, rather
than just the ribosomal bands, to assess the presence or
absence of degradation products. A RIN is calculated by
the software that interprets a sample’s RNA electrophe-
rogram, independent of concentration, and assigns a
number between 1 (highly degraded) and 10 (intact) [37].
Samples that passed these criteria were immediately shipped
overnight on dry ice to a CLIA (Clinical Laboratory
Improvement Amendments) certified external contract
laboratory (CRL). Samples failing any of these QC param-
eters were not sent for pathological review and were cen-
sored from the study and classified as a fail.
Pathological assessment and diagnosis
The primary pathological assessment was made using the
H&E sections from the OCT embedded snap frozen tis-
sue, taken immediately adjacent (above and below) to the
50 μM sections used for the RNA extraction. In the event
that the OCT H&E section were unavailable (e.g. the tis-
sue couldn’t be cut at 5 μM sections) the H&E section
from the FFPE tissue (derived from the same tumor mass)
was used. In either case, the pathologist was provided with
H&E images from both sample types, in the event that the
snap frozen H&E section was not of sufficient quality to
make a clear diagnosis and determination of tissue com-
position. The tissue sections were assessed for % viable
tumor (by Nuclei), % viable normal tissue (by nuclei) and
% Necrosis; to pass QC these values needed to be ≥50%,
<50% and ≤20%, respectively. Failure of any of these QC
parameters resulted in censoring from the study and clas-
sification as a fail.
Gene expression analysis
Upon receipt of the sample at the CLIA Certified Labora-
tory the following day (Day 2), the RNA samples were
held and processing delayed until the results of the patho-
logical assessment were available. Samples, that passed
pathological QC, were then subject to a second RNA QC
(as described above) as required by the CLIA laboratory
Standard Operating Procedure (SOP) to ensure no loss
in RNA integrity during shipment and thaw. Fifty nano-
grams of total RNA was used for cDNA synthesis and
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(NuGEN Technologies, Inc. CA), following which add-
itional cDNA QC checks were performed (total cDNA
yield ≥5 μg, A260/280 ≥1.8). Following fragmentation
and labeling (NuGEN Encore Biotin Module) the cDNA
was hybridized overnight to the Affymetrix Canine 2.0
array. The arrays were then washed, labeled (GeneChip
Hybridization, wash and stain kit, Affymetrix, Inc. CA.)
and scanned using the Affymetrix gene chip scanner
3000 7G. The image file produced by the scanner was
subsequently analyzed using the Affymetrix Expression
Console producing .CEL and .DAT files, from which add-
itional post-analysis QC pass/fail criteria were recorded,
including, background (<100), percent present (>30%),
scale factor (<100), spiked controls: 3’ signal (bioB <
bioC < bioD < cre) and a visual inspection of the image
file for surface anomalies. Post-analysis QC failures would
result in the data not being submitted for PMed report gen-
eration. Upon passing all criteria, a MAS5.0 normalization
process was performed producing a tab delimited pivot
table with probe identifiers, quality scores, present calls,
and intensities. All quality information and data files along
with the original image files were uploaded to a secure FTP
site hosted at VARI.
Bioinformatics and PMed report generation
The overall PMed system developed at VARI has been
described in detail elsewhere [38,39]. The iteration of the
system used for this study leverages several published
methodologies (see below) that attempt to identify bio-
pharmaceutical agents/natural products with predicted effi-
cacy on the basis of differentially expressed genes (DEGs)
in the sample(s) of interest. Each individual method uses a
series of assumptions, and each has the capacity to predict
the efficacy of a defined number of agents (with some over-
lap between methods). For this study, only agents approved
by the FDA for human use (in any disease indication) were
included. Additional file 1: Table S1 lists the 183 agents
that could have been predicted by at least one method
in this study, along with information on canine dosing if
known at the duration of the study. The input to all
methods is the normalized Z-score for a given Affymetrix
probe set which, as described above, represents the ex-
pression of a gene in the OSA sample in terms of the
number of standard deviations from the mean in the refer-
ence sample set (normal bone).
The initial step for processing each canine array is to
convert the probe set intensities for each tumor sample
to Z-scores using the reference set statistics (see above).
A Z-score (or standard score) is a numerical value that
indicates how many standard deviations a data point is
above or below the mean of the whole data set. Since
the PMed system was built on the basis of the human
Affymetrix GeneChip, a key step in the process was theconversion of canine Affymetrix Z-score data to the hu-
man counterpart. This was achieved by initial mapping
the Affymetrix GeneChip data to canine Entrez Gene
version 21 annotation. In the cases where multiple probe
sets mapped to the same gene they were aggregated
using the arithmetic mean to a single value for the cor-
responding canine Entrez Gene identifier. The canine
Entrez gene identifiers were then converted to human
Entrez Gene homolog using the National Cancer Institute’s
Homologene database (dated 11/15/2010). Any canine
Entrez Genes that could not be concisely mapped to
their human homolog were removed. Finally, the human
Entrez Gene identifiers (preserving the canine Z-score
data) were mapped to the appropriate Affymetrix U133
2.0 plus probe set ID using the Affymetrix U133 2.0 plus
annotation version 31 data file.
Biomarker rules
This method uses simple binary logic biomarker rules to
indicate or contraindicate specific agents [32]. The bio-
marker rules are established on the basis of vetted litera-
ture and compiled in a database in the simple form: IF
biomarker expressed > or < predefined Z-score value THEN
DO or DO NOT recommend drug. While each biomarker-
drug rule can be weighted on the basis of the disease con-
text of published findings, the iteration of the system used
in this study assumed equal weighting for all biomarker
rules irrespective on disease context (e.g. a biomarker rule
established in the context of lung cancer (e.g. ERCC1 as a
marker of cisplatin resistance) would be utilized in this
feasibility study).
Drug target expression
This is analogous to the biomarker rules approach de-
scribed above except that it relies exclusively on the known
mechanism of action of each agent, and does not require
well vetted literature to demonstrate an association be-
tween the expression of the drug target and the drug’s
efficacy. This method utilizes a human drug-target (mech-
anism of action) knowledge base developed from various
sources including DrugBank [31], MetaCore (Thomson
Reuters / GeneGo), MedTrack, PharmGKB, UpToDate
and DrugDex (Thomson Reuters). In this study, drug tar-
gets found to be over-expressed (based upon a Z-score
threshold of ≥ +3) in a patient’s tumor relative to the refer-
ence set were identified along with the agent that inhibits
the targets activity.
Drug response signatures
The Connectivity Map concept was initially developed
by the Broad Institute in an attempt to connect molecu-
lar signatures of disease with drug-induced changes in
gene expression [34]; drugs that are shown to induce
changes in gene expression in a set of cancer cell lines
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mal levels are identified as therapeutic candidates. In
our study, the maximum number of DEG’s submitted to
this algorithm were capped at 500 (the Z-score threshold
for this method was set to ≥ + 2.0 or ≤ −2.0) and the
method used rank-based statistics to identify candidate
drugs as described previously [34].
Drug sensitivity signatures
This method adopts Parametric Gene Set Enrichment
Analysis (PGSEA) using the NCI-60 cell line drug sensitiv-
ity signatures [33]. Gene expression signatures associated
with differential response to specific drugs on the basis of
the NCI 60 cell line in vitro drug screen are compared
to the tumor-derived gene expression signature. This
approach is consistent with well-published methods for
inferring drug sensitivity utilizing the NCI-60 cell line
dataset and baseline gene expression signatures [40-42].
Network target activity
This method predicts the activity (vs. expression) level
of drug targets on the basis of a specific type of molecular
network analysis referred to as topological analysis which
has been described previously [35]. It utilizes the DEG list
and pre-requisite knowledge of protein-protein interac-
tions within the knowledge-base of MetaCore (Thomson
Reuters/GeneGo) to build complex networks and predict
upstream target activity on the basis of observed down-
stream transcriptional events.
PMed report generation
Each of the methods summarized above produces a p-value
which is used to score and rank the predicted efficacy of
identified agents within each methodology. In addition, a
summated drug score (sum of – log (p)) was provided
as a means to further rank potential agents, along with
additional evidence supporting the potential use of the
agent in the context of the patient’s disease. For example,
current clinical trials and literature evidence identified
through an automated search of the disease context
(“osteosarcoma”) and the identified drugs were compiled
within the PMed report and provided as a further means
to select viable agents. The compiled interactive PMed re-
port was then distributed via PDF format to ACI and the
enrolling veterinarian. An example of a PMed report pro-
vided during the course of this study (for Subject TL-141)
is provided in Additional file 2 (PMed Report TL-141).
Results
The study accrual time for the enrollment of the 20 sub-
jects was 5 months (first biopsy AH-301 - 6/10/2011 to
final biopsy RB-187 - 11/10/2011). Table 3 highlights the
patient demographics and the dates of enrollment (date
of biopsy) for all 20 subjects. The main objective of thestudy was to assess feasibility in the distribution of a
subject-tumor specific PMed report in 5 business days
from receipt of the sample. As highlighted in Figure 1,
the logistics of this study involved multi-site participa-
tion and close monitoring of all aspects of the process
including, sample shipping, tissue processing, pathological
assessment, gene expression profiling, data management
and bioinformatics. Numerous QC criteria were included
throughout the study, to monitor the quality of both the
samples and the data generated with the goal of providing
the highest quality data as input into the PMed system.
The VARI generated RNA and pathology QC for all sub-
jects is shown in Table 4. The site specific pathology is
also presented in Table 4, although these diagnoses were
not part of the pathological QC as the turnaround time
for routine clinical samples was frequently greater than
7 days, and thus insufficient within the time restraints of
the study goal.
Of the 20 subjects recruited onto this study, 7 failed
QC and were not profiled. None of the samples that
were submitted for expression profiling failed post-array
QC assessment. Table 5 lists the subjects that failed QC
and provides the details for their exclusion. RIN failure
at both VARI and/or CRL accounted for attrition of 4/7
samples. In addition, 2/7 samples failed pathological QC,
whereas 1/7 samples was lost due to a shipping error
from the clinical site. In the cases of samples that passed
RIN QC but failed VARI Pathology QC (e.g. FS-203 and
NC-162 – see Figure 2), the external contract laboratory
was immediately notified and Affymetrix profiling aborted.
VARI was also notified by the external contract laboratory
if samples failed their RNA QC. If the external contract la-
boratory RIN QC was below 6.0 then upon consultation
with VARI, Affymetrix processing was aborted. In the two
cases where no RIN could be generated (i.e. an error
was flagged by the Agilent software (see note 3 in Table 4))
but the electropherogram passed visual inspection (e.g.
FS-202 and RB-187), VARI provided the go ahead to
proceed with Affymetrix gene expression profiling. In
each of these two cases the error was due to an unex-
pected peak in the fast lane which, upon changing this
threshold to 1 (this was only performed at VARI, since
due to the CLIA SOP, CRL was not able to change the
analysis settings of the Agilent Bioanalyzer), resulted in
a calculated RIN that was in excess of 8.
Robust and reproducible data is important to studies
of this type where samples are handled and analyzed in-
dividually. To address the overall data quality, Principal
Component Analysis (PCA) was performed on both the
5 normal bone samples and 14 qualified osteosarcoma
tumors (Figure 3). A secondary measure to address assay
precision included the addition of a biological replicate,
identified as VS-01, which was isolated from a second
piece of tumor from subject VS-121. PCA analysis clearly
Table 3 Patient demographics
Enrollment order Patient ID DOB Sex1 Breed Date of biopsy Disease location Medullary or
Extramedullary
1 AH-301 9-Jun-06 MC Belgian Malinois 10-Jun-11 Right Distal radius Extramedullary
2 FS-201 19-Aug-02 MC German Short-Hair Pointer 20-Jun-11 Right Proximal Femur Medullary
3 RV-281 1-May-03 M Coonhound 21-Jul-11 Left Proximal Humerus Medullary
4 MH-101 27-Jul-04 FS German Shepherd 2-Aug-11 Right Distal Tibia Extramedullary
5 TL-141 1-Aug-05 MC Standard Schnauzer 17-Aug-11 Right Distal Femur Extramedullary
6 RB-181 3-Aug-00 FS Labrador Retriever 19-Aug-11 Right Proximal Tibia Medullary
7 RB-182 1-Jan-03 MC German Shepherd 01-Sep-11 Right Distal tibia Not determined
8 RB-183 1-Apr-99 FS Golden Retriever Mix 3-Sep-11 Right Distal Femur Medullary
9 VS-121 13-Feb-09 FS Golden Retriever 6-Sep-11 Right Proximal Tibia Extramedullary
10 AZ-221 20-Aug-06 FS Greyhound 7-Sep-11 Right Proximal Humerus Not determined
11 RV-282 2-Jan-04 MC Labrador Retriever 8-Sep-11 Right Proximal Humerus Medullary
12 NC-161 13-Sep-01 FS Golden Retriever 13-Sep-11 Left Distal Radius Extramedullary
13 FS-202 16-Sep-99 FS Greyhound 24-Sep-11 Right Proximal Humerus Medullary
14 FS-203 3-Apr-02 FS Labrador Retriever 29-Sep-11 Right Proximal Humerus Extramedullary
15 RB-184 23-May-04 FS Great Dane 1-Oct-11 Left Proximal Tibia Medullary
16 RB-185 20-Aug-00 FS Greyhound 5-Oct-11 Left Proximal Humerus Medullary
17 RB-186 4-Mar-04 MC Lab Mix 10-Oct-11 Left Distal Ulna Both*
18 RV-283 22-Apr-04 FS Great Dane 20-Oct-11 Right Distal Femur Extramedullary
19 NC-162 24-May-04 M German Shepherd 31-Oct-11 Right proximal Femur Medullary
20 RB-187 3-Nov-04 M Rottweiler 10-Nov-11 Right Distal Ulna Both*
1 Sex – M – Male; MC - Male castrated; FS – Female Spayed.
* Both indicates cases in which medullary and extramedullary locations were sampled.
Monks et al. Journal of Translational Medicine 2013, 11:158 Page 9 of 16
http://www.translational-medicine.com/content/11/1/158reveals a difference between normal and tumor tissue at
the level of the 1st and 2nd principle components (the
components contributing to the most variance), the 5x
total bone harvests from disease-free subjects (green data
points) clearly separate from the osteosarcoma tumor tis-
sue (red data points). Additionally, within the same tumor
sample, biological replicates (VS-121 and VS-01, isolated
from 2 separate pieces of the same tumor) co-cluster
tightly (blue data points), demonstrating a high level of re-
producibility between the replicates and thus providing
confidence that comparative analyses can be made be-
tween all data generated in the study. Furthermore, the
PCA also reveals the degree of genomic heterogeneity
between the different OSA tumor samples, supporting
the use of a PMed approach to the selection of suitable
therapies on the basis of molecular profiling.
The primary objective for the study was to determine
the feasibility of processing a tumor biopsy through to
PMed report generation and distribution to the veteri-
narians in 5 working days. Table 6 displays the data
pertaining to the PMed report turnaround time, highlight-
ing the dates of surgery, sample receipt at VARI, shipment
of pre-qualified RNA to CRL, data receipt back from CRL,
and the date on which the PMed report was distributed
(via email) to ACI.Day 1 was considered to be the day on which the sam-
ples arrived at VARI. There were however two exceptions;
those samples received on a Friday, Day 1 was automatic-
ally defaulted to Monday (or the next business day). This
process was instigated to avoid the shipment of samples
to the external contract laboratory into the weekend. 8
of the 20 samples were handled in this manner (see
footnote 1 in Table 6).
The total turnaround time was calculated as the num-
ber of days from the receipt of the sample at VARI to
the date on which the PMed report was sent (Table 6).
The final turnaround time was adjusted to account for
weekends and public holidays. In the majority of cases
the PMed reports were released within 5 business days.
Two subjects, RB-182 and FS-202, failed this objective.
RB-182 was received on a Friday and thus processing
was delayed to the next business day, as the following
Monday was a public holiday, processing should have
started on the Tuesday. However, due to the absence of
critical histopathology staff, the start of processing was
delayed until the Wednesday. FS-202 was processed and
data received on schedule for a 5 day turnaround. How-
ever, due to the loss of connectivity between the PMed
system and an external database, the PMed report was
delayed until the Sunday.
Table 4 VARI RNA and pathological QC
Patient ID RNA QC Pathology QC




VARI diagnosis Clinical site diagnosis
(1st Cut / 2nd Cut)
AH-301 2.27 8 75/75 5/10 20/15 Chondrosarcoma Chondrosarcoma
FS 201 2.08 7.8 80/80 20/20 15/25 Poorly differentiated tumor.
Atypical Osteosarcoma
OSA
RV 281 2.11 9.3 75/75 20/20 10/10 Osteosarcoma Chronic suppurative inflammation
MH 101 1.84 5.52 No Pathology due to RNA
QC failure
OSA
TL-141 2.11 6.8 60/50 30/50 10/0 Osteosarcoma. OSA
RB-181 2.11 7.5 80/85 10/5 10/10 Osteosarcoma OSA
RB-182 2.07 8.5 60/60 20/30 20/10 Osteosarcoma OSA
RB-183 2.09 6.8 90/80 10/10 0/10 Osteosarcoma (FFPE) OSA
VS 121 2.06 6.4 90/95 5/0 5/5 Osteosarcoma with a differential
diagnosis of undifferentiated sarcoma.
OSA
AZ-221 2.09 8.1 50/50 50/40 0/10 Osteosarcoma (FFPE) OSA
RV-282 Sample lost due to shipping delay. OSA
NC-01 2.1 8 80/80 15/10 5/10 Osteosarcoma. OSA
FS 202 2.09 8.53 60/65 30/25 10/10 Osteosarcoma. (Frozen and FFPE) OSA
FS 203 2.03 7.2 No evidence of tumor,
values not recorded
No evidence of tumor
(Frozen and FFPE)
Chronic inflammation
RB 184 2.15 6.84 65/70 30/30 5/0 Osteosarcoma. OSA
RB 185 1.8 6.9 90/75 5/20 5/15 Osteosarcoma. (FFPE) OSA
RB 186 2.11 5.42 No Pathology due to RNA QC failure OSA
RV 283 2.09 8.4 60/60 40/40 0/0 Undifferentiated sarcoma (FFPE). OSA
NC 162 2.08 7.4 0/0 70/70 30/30 Normal tissue. Not available
RB 187 2.09 8.63 65/65 25/25 10/10 Osteosarcoma Suspected Synovial carcinoma
1 - Scores based on % nuclei.
2 - Failed RIN.
3 No RIN generated by Agilent software, even though sample visually looks good. Altered Fast lane threshold (to 1) to obtain RIN.


















Table 5 Samples that failed QC and reason for exclusion from the PMed analysis
Patient ID Reason for exclusion from study
MH-101 Failed RIN at VARI (5.5) 1
RB-183 Failed RIN at CRL (no score generated)
RV-282 Samples shipped 9/8/2001 overnight, scheduled to arrive on Friday 9/9/2011. Actual arrival 9/12/2011.
Dry ice evaporated and sample was at RT.
FS-203 Failed Pathology QC (No neoplastic tissue observed).
RB-185 Failed RIN at CRL (5.8) 1
RB-186 Failed RIN at VARI (5.4) 1
NC-162 Failed Pathology (No neoplastic tissue observed)
1 All samples submitted for GeneChip analysis passed RIN at both VARI and CRL.
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provide critical information regarding the considerations
that be need to be addressed in guiding the design of fu-
ture canine PMed studies. Refining the logistics through
the identification of the possible failure points in the
process are important metrics that were addressed in the
primary objective of this study. These findings will be
used to design future PMed trials, with the expectant
outcome being a reduced rate of attrition for the en-
rolled subjects. Moving forward, the study designs will
also include a treatment phase that will rely upon the ef-
fective use of the PMed report by the Veterinarians.
Therefore clinician feedback was captured regarding their
impressions following the receipt of the PMed report for
their patient(s). A deeper understanding of the clinicians
thoughts and concerns related to the report presentation
will assist in our understanding of how best to present the
data to the clinician and support their decision making;
with the ultimate aim of providing an informed drug
prioritization schema to aid in their prospective treatment
decisions. In general the PMed reports were well receivedFigure 2 Representative images taken from FFPE sections of subjects
osteosarcoma displaying multinucleated tumor osteoblast and osteoid syn
respectively) correspond to samples that failed VARI pathology QC as theyand found to be easy to read and presented in an accept-
able format. An example report for subject TL-141 is
provided in the Additional file 2. Support for additional
treatment based PMed trials based on the predictions
provided in the PMed report was supported by an over-
whelming 85% of clinicians, who stated they would con-
sider using the report under the appropriate circumstances.
This encouraging feedback, together with their constructive
comments suggest that additional support and education
regarding the information in the report and approaches to
address drug availability, cost and canine dosing, would be
critical factors in the implementation of a suitable thera-
peutic strategy based on the PMed reports.
Discussion
Establishing a robust protocol, which is adaptable to the
inherent challenges that can arise whilst working with
clinical samples in real time, is critical to the success of
any trial. In this report we have highlighted a protocol,
and the challenges we faced, that will prove invaluable
in the design of a prospective personalized medicineenrolled in the study. A (RB-181) and B (RB-183) highlight classical
thesis. The histologies shown in Figures C and D (FS-203 and NC-162,
failed to show evidence of a suitable proportion of neoplastic disease.
Figure 3 Principal component analysis (PCA). 43,035 probe sets
clearly distinguishing normal bone (green) from OSA samples (red).
The biological replicates (VS-121 and VS-01) highlighted in blue and
show minimal variance.
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http://www.translational-medicine.com/content/11/1/158treatment trial in canines with osteosarcoma. Osteosar-
coma was an excellent candidate tumor to study for
number of reasons. Firstly, it is an extremely common
disease in large breeds, with an incidence estimated to
be around 13.9/100,000 [18]; these numbers will have a
positive impact on the rapid recruitment of study partici-
pants. Secondly, although amputation and adjuvant chemo-
therapy have been shown to be extremely effective in the
short term, the long term survival is poor and the current
armamentarium for canine osteosarcoma are restricted to
combinations of classical cytotoxic agents e.g. doxorubicin
and platinum compounds (reviewed in [24]). Current
therapeutic development for canine osteosarcoma in-
volves the modification of current protocols and Standard
of Care (SOC) agents with limited success [43], rather
than the integration of new therapeutic agents as single or
combinational therapy. Personalized medicine strategies
provide an opportunity to expand a patient’s “therapeutic
opportunities” by examining the molecular/biological
factors that are fundamental to that individual’s disease
etiology and progression. Using various bioinformatics
methods described here that integrate both classical
chemotherapeutics with a large library of molecularly
targeted agents designed to inhibit intracellular targets,
agents that block the drivers of the disease phenotype
can be identified. At present, PMed approaches in veterin-
ary oncology are limited to the administration of toceranib
or masitinib in dogs with mast cell tumors containing
c-kit mutations [44]. The translational value of canine
osteosarcoma provides a vital opportunity to further re-
fine the PMed approach through the application of drug
predictions to treatment of naïve tumors in a clinicaltrial, an opportunity that is not possible in human trials.
Finally, the generation of data that can be directly related
to the corresponding human disease, due to the close
similarity of OSA in both species at multiple levels, makes
it an excellent translational model for evaluating the prin-
ciples of personalized medicine.
Sampling and handling of canine OSA tumors pro-
vides a unique set of challenges. Firstly, the precise loca-
tion of the tumor for sampling could have a significant
effect on the sample quality, i.e. the heterogeneity in the
proportion of tumor tissue versus normal, and the differ-
ing extents of necrosis. Standardization with strict QC/
QA was therefore critical and addressed by providing site
specific training to the veterinary surgeons, to assist in the
identification of the most suitable, viable tumor tissue for
collection. Care was taken to harvest samples that were
free of necrosis and not overly lytic located along the non-
mineralized periphery of the tumor. The presence of cor-
tical bone in the samples was also a challenge that was
faced in this study as this could impede the processing
of both the formalin fixed and snap frozen tissue. Prior
to paraffin embedding, the formalin fixed tissue was
decalcified for 3 hours in a solution containing formic
acid. The snap frozen tissue was initially treated as
bone-free and embedded in OCT for sectioning; any tissue
that did not section in the cryotome, was removed from
OCT, ground in liquid nitrogen, followed by RNA extrac-
tion in Trizol. As such, it was impossible to make the
pathology reads from the OCT sections above and below
those utilized for RNA, and in these cases the formalin
fixed tissue was used as an appropriate surrogate.
Using the work flows and processes described in this
study, we have demonstrated that it is feasible to process
canine osteosarcoma samples received from multiple clin-
ical sites and distribute a molecularly-guided, personalized
medicine (PMed) report within 5 business days (Table 6,
Final Turnaround Mean = 5.08 ± 0.8 days) from the time
of sample receipt. Seven of the 20 samples enrolled in the
study were not submitted for Affymetrix GeneChip profil-
ing due to failure of genomic or pathological QC (6/7) or
transportation problems (1/7). Thirteen samples were
successfully genomically profiled, of which 11 were dis-
tributed to the veterinary clinicians within the 5 business
day target. 2 samples failed the 5 day turn around, one
due to staff shortages, and the second due to a database
access failure which stalled the generation of the PMed
report. This feasibility study has highlighted a number
of critical failure points in the logistics of producing a
timely PMed report. Within a restricted time frame,
pathological QC failure is the most challenging criteria
to address, as this, in most cases, would require add-
itional sampling of the tumor. Repeat sampling of the
original tumor fragment could address the issues of het-
erogeneous normal tissue contamination and necrosis.
Table 6 Details of the study timing and turnaround
Patient ID Date Turnaround (Days)
Surgery date Arrival at VARI RNA Shipped to CRL Date data uploaded from CRL PMed Report sent Total days from sample




AH-301 6/10/2011 Fri 6/13/2011 Mon 6/13/2011 Mon 6/16/2011 Thu 6/17/2011 Fri 5 0 5
FS-201 6/20/2011 Mon 6/21/2011 Tue 6/21/2011 Tue 6/27/2011 Mon 6/27/2011 Mon 2 7 −2 5
RV-281 7/21/2011 Thu 7/22/2011 Fri 1 7/25/2011 Mon 7/28/2011 Thu 7/29/2011 Fri 7 −2 5
MH-101 8/2/2011 Tue 8/3/2011 Wed Failed RNA QC (RIN) at VARI
TL-141 8/18/2011 Thu 8/19/2011 Fri 1 8/22/2011 Mon 8/25/2011 Thu 8/26/2011 Fri 7 −2 5
RB-181 8/19/2011 Fri 8/25/2011 Thu 8/25/2011 Thu 8/31/2011 Wed 8/31/2011 Wed 7 −2 5
RB-182 9/1/2011 Thu 9/2/2011 Fri 1 9/7/2011 Wed 9/13/2011 Tue 9/13/2011 Tue 11 -(4 3 + 1 4) 6 5
RB-183 9/3/2011 Sat 9/8/2011 Thu 9/8/2011 Thu Failed RNA QC (RIN) at CRL
VS-121 9/6/2011 Tue 9/7/2011 Wed 9/7/2011 Wed 9/13/2011 Tue 9/13/2011 Tue 7 −2 5
AZ-221 9/7/2011 Wed 9/8/2011 Thu 9/8/2011 Thu 9/13/2011 Tue 9/13/2011 Tue 6 −2 4
RV-282 9/8/2011 Thu 9/12/2011 Mon 6 Sample lost due to shipping error.
NC-161 9/13/2011 Tue 9/15/2011 Thu 9/15/2011 Thu 9/20/2011 Tue 9/20/2011 Tue 6 −2 4
FS-202 9/24/2011 Sat 9/30/2011 Fri 1 10/3/2011 Mon 10/7/2011 Fri 10/9/2011 Sun 9 −2 7 7
FS-203 9/29/2011 Thu 9/30/2011 Fri 1 10/3/2011 Mon Failed pathology QC.
RB-184 10/1/2011 Sat 10/5/2011 Wed 10/5/2011 Wed 10/11/2011 Tue 10/11/2011 Tue 7 −2 5
RB-185 10/5/2011 Wed 10/7/2011 Fri 1 10/10/2011 Mon Failed RNA QC (RIN) at CRL
RB-186 10/10/2011 Mon 10/14/2011 Fri 1 Failed RNA QC (RIN) at VARI
RV-283 10/20/2011 Thu 10/21/2011 Fri 1 10/24/2011 Mon 10/27/2011 Thu 10/28/2011 Fri 7 −2 5
NC-162 10/31/2011 Mon 11/2/2011 Wed 11/2/2011 Wed Failed pathology QC.
RB-187 11/10/2011 Thu 11/16/2011 Wed 11/16/2011 Wed 11/22/2011 Tue 11/22/2011 Tue 7 −2 5
1 Samples received on Fridays were automatically defaulted to start on Mondays (Day 1).
2 Report generated manually on Monday June 27th 2011 due to PDF conversion problems within the software. Corrected report sent out the following day (Tuesday June 28th 2011).
3 Two weekends (4 Days).
4 Sample processing delayed 1 day (9/5/2011) due to Labor Day holiday.
5 One day lost due to absence of critical Histopathology staff.
6 Sample did not arrive on time (due Friday September 9th 2011) arrived thawed on the following Monday (September 12th 2011).


















Monks et al. Journal of Translational Medicine 2013, 11:158 Page 14 of 16
http://www.translational-medicine.com/content/11/1/158RNA quality, primarily assessed through the determin-
ation of RIN number, was found to be the single largest
cause of sample attrition. Our experience has identified
that re-sectioning (deeper into the tissue fragment) and
repeat RNA isolation can, in the majority of cases, pro-
duce higher quality RNA. The 5-business day time con-
straints did not provide sufficient time to re-address
those samples with a low RIN or failed Pathology. A rec-
ommendation for a future PMed clinical trial would be
to increase the turnaround time from 5 to 7 business
days, thereby providing additional time to re-process
samples as necessary. Additionally, the RNA RIN QC
will be raised from ≥6 to ≥7, therefore only samples with
a RIN of ≥7 will be shipped, this would address samples
RIN QC failure at the external contract laboratory,
resulting from degradation of the RNA most likely due
to repeated freeze-thaw cycles after shipment. While
these modifications will slightly increase the maximum
time required for sample processing within the confines
of a real-time clinical protocol, it should nonetheless
significantly reduce the rate of attrition due to low quality
RNA. With specific reference to this study, an improved
quality of RNA would have the potential to increase the
overall pass rate from 65% to 85%. Additionally, based on
current canine osteosarcoma SOC clinical protocols for
patients following amputation, there is considerable flexi-
bility to permit an increase in the turnaround from 5 to 7
business days. Adjuvant therapy usually commences fol-
lowing a 14 day surgical recovery period as it has been
shown that there is no additional patient benefit to
starting chemotherapy soon after surgery [45].
While the primary goals of the study were achieved
and the pitfalls identified, the success of a prospective
PMed clinical trial is dependent upon the commitment
and active participation of the clinical veterinarians. To
further improve the infrastructure necessary to support
the clinicians and identify the specific challenges that will
be faced while implementing adjuvant therapies, opinions
were captured from the participating clinicians. Based
upon the responses, the reaction to the PMed reports was
overall positive, and useful information was provided that
will be used to steer the development of a prospective
clinical trial protocol in the future. As with human trials,
the role of a multidisciplinary tumor board will be critical
in advising the clinician as to the appropriate therapy(s).
One particular challenge that will need to be addressed in
future studies will be the lack of established canine dosing
for the FDA approved medications identified through our
PMed approach. This has been addressed in a cursory
review (see Additional file 1: Table S1) although a more
comprehensive evaluation is certainly warranted and
will most likely involve a restricted drug list in which
there is known canine use. Furthermore, a prospective
PMed trial in which most suitable therapies are appliedto the patients will need to offer drug reimbursement as
an incentive to owners to enroll their companion pets.
Conclusions
The data presented in this report demonstrate that it is
possible to provide a PMed report to the veterinarian in
5 days from receipt of sample. This feasibility study has
identified a number of areas of the protocol that can be
enhanced to reduce the number of samples that fail the
QC criteria established to maintain the integrity of the
PMed predictions. Additionally, a number of weaknesses
have been identified post-report distribution, which can
be addressed to assist in the clinical interpretation and
application of the PMed report towards selection of the
most appropriate therapy. Moreover, while our current
approach leverages molecular technologies and associated
bioinformatics approaches for analysis of gene expression,
the recent emergence of next-generation sequencing tech-
nologies holds additional promise for identifying add-
itional genomic aberrations (mutations) within individual
patient tumors that may provide a more complete de-
piction of the multiple facets which collectively com-
prise the cancer phenotype (Discussed in [46-48]).
Whether these more advanced technologies, including the
computational tools required to analyze and interpret the
vast quantities of data, can be performed in a time and cost
effective manner remains to be determined.
Additional files
Additional file 1: Table S1. PMed Drug list reviewed for Canine use
and dosing.
Additional file 2: Example PMed Report for subject TL-141.
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